The Natural History of Upper Arm Vessels After Placement of a Forearm Arteriovenous Graft: A Pilot Study

Brian J. Benes

Follow this and additional works at: https://digitalcommons.unmc.edu/gmerj

Part of the Higher Education Commons, and the Medicine and Health Sciences Commons

Recommended Citation

This Conference Proceeding is brought to you for free and open access by DigitalCommons@UNMC. It has been accepted for inclusion in Graduate Medical Education Research Journal by an authorized editor of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.
Among patients with marginal vessel diameter was assessed by ultrasound, arteriovenous fistulas (AVF) may be a preferred alternative. Prior studies demonstrated proximal vessel remodeling after AVG creation, but timing of these changes is unknown. In this pilot study, we aimed to determine the timing and degree of vessel remodeling following AVG creation.

Methods: We prospectively evaluated the basilic and cephalic veins, and brachial artery in 10 patients undergoing AVG placement. Vessel diameter was assessed by ultrasound prior to surgery and at 1, 4, 12 and 27 weeks post-AVG, and compared across the respective time points. The brachial artery was measured near the antecubital fossa, while the cephalic and basilic vein were measured at the antecubital fossa (AC), mid upper-arm (MID), and proximal upper-arm (UP).

Results: Basilic vein diameter increased at week one across all sites and continued to increase through week 12. The change in the cephalic vein was less than the basilic vein, but the AC location increased from baseline to week 12. The increase in mean brachial artery diameter reached significance at week 12.

Cost Analysis of Reducing Peri-Operative Eye Drop Regimen at the VA Health System
Colby L. Argo1,2, Santi S. Karnam1,2, Millicent Palmer-Johnson2
1Department of Ophthalmology, College of Medicine, University of Nebraska Medical Center
2Department of Ophthalmology, Veteran’s Administration Hospital

Mentor: Millicent Palmer-Johnson
Program: Ophthalmology
Type: Original Research

Background: Eye surgeries are one of the most commonly performed procedures worldwide. Improved surgical techniques and instrumentation have significantly decreased the number of complications and provided the opportunity to reduce the need for topical eye medications. We aim to examine the potential financial benefits to the VA health care system after implementing a reduced peri-operative eye drop schedule.

Methods: After reviewing the costs of various peri-operative eye drops obtained through the Veteran’s Administration Hospital, analysis was conducted on the potential risks and benefits of each medication. It was determined that dexamethasone 0.1%, neomycin sulfate 3.5mg/mL and polymyxin B sulfate 10,000 U/mL (Maxitrol®) can act to prevent post-operative complications while allowing for simpler instruction to patients, which would reduce confusion and potentially improve medication compliance. Ketorolac 0.5% would only be used in patients at increased risk of developing cystoid macular edema (previous history of diabetic retinopathy or uveitis). A cost-analysis was then performed for the current and proposed drop regimens. A pre- and post-implementation survey will be given to the ancillary staff and physicians to determine the effects of the implementation.

Results: The costs of the current and reduced peri-operative drop regimen were calculated (Table 1). A cost reduction of 58.6% to 81.5% was calculated depending on the optional addition of Ketorolac.

https://doi.org/10.32873/unmc.dc.gmerj.4.1.039

Cost Analysis of Reducing Peri-Operative Eye Drop Regimen at the VA Health System
Colby L. Argo1,2, Santi S. Karnam1,2, Millicent Palmer-Johnson2
1Department of Ophthalmology, College of Medicine, University of Nebraska Medical Center
2Department of Ophthalmology, Veteran’s Administration Hospital

Mentor: Millicent Palmer-Johnson
Program: Ophthalmology
Type: Original Research

Background: Eye surgeries are one of the most commonly performed procedures worldwide. Improved surgical techniques and instrumentation have significantly decreased the number of complications and provided the opportunity to reduce the need for topical eye medications. We aim to examine the potential financial benefits to the VA health care system after implementing a reduced peri-operative eye drop schedule.

Methods: After reviewing the costs of various peri-operative eye drops obtained through the Veteran’s Administration Hospital, analysis was conducted on the potential risks and benefits of each medication. It was determined that dexamethasone 0.1%, neomycin sulfate 3.5mg/mL and polymyxin B sulfate 10,000 U/mL (Maxitrol®) can act to prevent post-operative complications while allowing for simpler instruction to patients, which would reduce confusion and potentially improve medication compliance. Ketorolac 0.5% would only be used in patients at increased risk of developing cystoid macular edema (previous history of diabetic retinopathy or uveitis). A cost-analysis was then performed for the current and proposed drop regimens. A pre- and post-implementation survey will be given to the ancillary staff and physicians to determine the effects of the implementation.

Results: The costs of the current and reduced peri-operative drop regimen were calculated (Table 1). A cost reduction of 58.6% to 81.5% was calculated depending on the optional addition of Ketorolac.

https://doi.org/10.32873/unmc.dc.gmerj.4.1.040